MCID: CHL152
MIFTS: 44

Childhood Acute Lymphocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Childhood Acute Lymphocytic Leukemia

MalaCards integrated aliases for Childhood Acute Lymphocytic Leukemia:

Name: Childhood Acute Lymphocytic Leukemia 12 52 15
Childhood Acute Lymphoblastic Leukemia 12 52 15
Pediatric Acute Lymphoblastic Leukemia 52
Childhood All 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0080144
NCIt 49 C3168

Summaries for Childhood Acute Lymphocytic Leukemia

NIH Rare Diseases : 52 Childhood acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow, and the most common type of cancer in children. In children with this condition, too many stem cells made by the bone marrow become lymphoblasts , B lymphocytes , or T lymphocytes . These cells do not function normally and have trouble fighting off infections. Signs and symptoms may include fever; easy bruising or bleeding; bone or joint pain; painless lumps in the neck, underarm, stomach, or groin; weakness; fatigue; and/or loss of appetite. Treatment depends on several factors and may include combination chemotherapy , targeted therapy , and/or stem cell transplant . On August 30 2017, Kymriah became the first gene therapy approved by the FDA. Kymriah is now an option for children and young adults up to 25 years old with B-Cell precursor ALL that has proven resistant to other treatments or has relapsed two or more times.

MalaCards based summary : Childhood Acute Lymphocytic Leukemia, also known as childhood acute lymphoblastic leukemia, is related to osteonecrosis and b-lymphoblastic leukemia/lymphoma with iamp21. An important gene associated with Childhood Acute Lymphocytic Leukemia is LOC105377938 (Uncharacterized LOC105377938), and among its related pathways/superpathways are MicroRNAs in cancer and Fluoropyrimidine Activity. The drugs Thiotepa and Oprelvekin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells.

Disease Ontology : 12 An acute lymphocytic leukemia occuring during childhood.

Related Diseases for Childhood Acute Lymphocytic Leukemia

Diseases related to Childhood Acute Lymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 400)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis 31.3 VEGFA MTHFR ABCB1
2 b-lymphoblastic leukemia/lymphoma with iamp21 30.7 LOC105377938 ETV6
3 adult acute lymphocytic leukemia 30.7 TYMS MTHFR ETV6
4 leukemia, chronic myeloid 30.6 VEGFA MIR18A MCL1 ETV6 ABCB1
5 childhood leukemia 30.5 TYMS SLC19A1 MTHFR ETV6 DHFR ARID5B
6 methotrexate toxicity 30.3 TYMS SLC19A1 MTHFR DHFR ABCB1
7 mucositis 30.3 VEGFA TYMS MTHFR ABCB1
8 brain cancer 30.0 VEGFA MIR18A ETV6 ARID5B ABCB1
9 leukemia, acute lymphoblastic 29.8 TYMS SLC19A1 NR3C1 MTHFR MIR18A MCL1
10 hematologic cancer 29.7 VEGFA NR3C1 MIRLET7F1 MIR18A MCL1 ETV6
11 childhood b-cell acute lymphoblastic leukemia 12.3
12 childhood t-cell acute lymphoblastic leukemia 11.6
13 leukemia 10.7
14 leukemia, acute myeloid 10.6
15 chromosomal triplication 10.6
16 splenomegaly 10.6
17 lipid metabolism disorder 10.5
18 severe combined immunodeficiency 10.5
19 lymphoma 10.4
20 idiopathic nephrotic syndrome 10.4 NR3C1 ABCB1
21 pediatric osteosarcoma 10.4 SLC19A1 MTHFR DHFR
22 hemifacial spasm 10.4 VEGFA TYMS MTHFR
23 central nervous system disease 10.4
24 nervous system disease 10.4
25 myeloid leukemia 10.4
26 lung non-squamous non-small cell carcinoma 10.4 VEGFA TYMS DHFR
27 soft tissue sarcoma 10.4 VEGFA ABCB1
28 retinoblastoma 10.4
29 graft-versus-host disease 10.4
30 testicular leukemia 10.4
31 familial retinoblastoma 10.4
32 branch retinal artery occlusion 10.4 VEGFA MTHFR
33 pleural cancer 10.4 VEGFA TYMS DHFR
34 bone mineral density quantitative trait locus 3 10.4
35 lymphoblastic lymphoma 10.4
36 t-cell acute lymphoblastic leukemia 10.4
37 neuropathy 10.4
38 47,xyy 10.4
39 acute graft versus host disease 10.4
40 differentiated thyroid carcinoma 10.4 VEGFA MTHFR ETV6
41 leukemia, chronic lymphocytic 10.3
42 body mass index quantitative trait locus 11 10.3
43 body mass index quantitative trait locus 1 10.3
44 peripheral nervous system disease 10.3
45 uterine benign neoplasm 10.3 VEGFA MIR18A CCNC
46 lymphoma, hodgkin, classic 10.3
47 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
48 central retinal artery occlusion 10.3 VEGFA MTHFR
49 hypertriglyceridemia, familial 10.2
50 wilms tumor 1 10.2

Graphical network of the top 20 diseases related to Childhood Acute Lymphocytic Leukemia:



Diseases related to Childhood Acute Lymphocytic Leukemia

Symptoms & Phenotypes for Childhood Acute Lymphocytic Leukemia

Drugs & Therapeutics for Childhood Acute Lymphocytic Leukemia

Drugs for Childhood Acute Lymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Oprelvekin Approved, Investigational Phase 4 145941-26-0
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Ethylene Phase 4 74-85-1 6325
6
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
7
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
8
Calcium carbonate Approved, Investigational Phase 3 471-34-1
9
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
10
Lenograstim Approved, Investigational Phase 3 135968-09-1
11
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
12
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
15
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
16
Acyclovir Approved Phase 3 59277-89-3 2022
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Tazobactam Approved Phase 3 89786-04-9 123630
19
Vancomycin Approved Phase 3 1404-90-6 14969 441141
20
Piperacillin Approved Phase 3 66258-76-2 43672
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
22
Captopril Approved Phase 3 62571-86-2 44093
23
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
24
Ribavirin Approved Phase 3 36791-04-5 37542
25
Palivizumab Approved, Investigational Phase 3 188039-54-5
26
Dasatinib Approved, Investigational Phase 2, Phase 3 302962-49-8 3062316
27
Ichthammol Approved Phase 2, Phase 3 8029-68-3
28
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
29
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
30
Mercaptopurine Approved Phase 3 50-44-2 667490
31
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
32
Amsacrine Approved, Investigational Phase 2, Phase 3 51264-14-3 2179
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
34
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
35
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
36
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
37
Etoposide Approved Phase 3 33419-42-0 36462
38
Mesna Approved, Investigational Phase 3 3375-50-6 598
39
Busulfan Approved, Investigational Phase 3 55-98-1 2478
40
Mycophenolic acid Approved Phase 3 24280-93-1 446541
41
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
42
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
43
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
44
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
46
Cortisone Experimental Phase 3 53-06-5 222786
47 Alkylating Agents Phase 2, Phase 3
48 Immunologic Factors Phase 2, Phase 3
49 Antirheumatic Agents Phase 2, Phase 3
50 Antacids Phase 3

Interventional clinical trials:

(show top 50) (show all 366)
# Name Status NCT ID Phase Drugs
1 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
2 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
3 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
4 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
5 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
6 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
7 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
8 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
9 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
10 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
11 TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS Unknown status NCT00002499 Phase 2, Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;dexamethasone;methotrexate;prednisone;vincristine sulfate
12 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
13 A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
14 A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation Unknown status NCT00450450 Phase 3
15 High Risk B-Precursor Acute Lymphoblastic Leukemia Unknown status NCT00075725 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
16 Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial Unknown status NCT00003437 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;thioguanine;vincristine sulfate
17 Treatment of Acute Lymphoblastic Leukemia in Children Completed NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
18 Diminished Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Severity-Adapted Clinical Trial Completed NCT00186901 Phase 3 Calcium carbonate (Tums), vitamin D
19 Nordic Society of Paediatric Haematology and Oncology Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults (18-45 Years of Age) With ALL. Efficacy of Individualised 6MP Dosing During Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
20 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
21 A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008. Completed NCT00707083 Phase 3 dexamethasone;mercaptopurine;methotrexate;vincristine sulfate
22 A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
23 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
24 EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY Completed NCT00002816 Phase 3 cytarabine;dexamethasone;etoposide;idarubicin;ifosfamide;leucovorin calcium;mesna;pegaspargase;therapeutic hydrocortisone;thioguanine;vincristine sulfate;Methotrexate
25 A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
26 NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion Completed NCT00819351 Phase 3 PEG Asparaginase at six weeks interval;PEG Asparaginase at two weeks interval
27 ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
28 ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study Completed NCT00005585 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
29 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
30 Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study Completed NCT00002812 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;idarubicin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
31 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
32 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
33 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
34 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
35 ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study Completed NCT00005603 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate
36 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
37 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
38 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
39 Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00005945 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
40 A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia Completed NCT01829711 Phase 3 Moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
41 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
42 Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia Completed NCT00002744 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisone;therapeutic hydrocortisone;thioguanine;vincristine sulfate
43 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
44 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
45 ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
46 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
47 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
48 A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia Completed NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus
49 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
50 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole

Search NIH Clinical Center for Childhood Acute Lymphocytic Leukemia

Genetic Tests for Childhood Acute Lymphocytic Leukemia

Anatomical Context for Childhood Acute Lymphocytic Leukemia

MalaCards organs/tissues related to Childhood Acute Lymphocytic Leukemia:

40
Bone, Bone Marrow, T Cells, B Cells, Myeloid, Brain, Testes

Publications for Childhood Acute Lymphocytic Leukemia

Articles related to Childhood Acute Lymphocytic Leukemia:

(show top 50) (show all 3499)
# Title Authors PMID Year
1
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines. 61
32311402 2020
2
COVID-19 and childhood acute lymphoblastic leukemia. 61
32400927 2020
3
Cardiac autonomic dysfunction in survivors of childhood acute lymphoblastic leukemia: The St. Jude Lifetime Cohort Study. 61
32383821 2020
4
Using Pharmacology to Squeeze the Life Out of Childhood Leukemia, and Potential Strategies to Achieve Breakthroughs in Medulloblastoma Treatment. 61
32571983 2020
5
Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia†. 61
32391957 2020
6
Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines. 61
32444028 2020
7
Association of population mixing and acute lymphocytic leukemia in children and young adults. 61
32353774 2020
8
Impact of Videotaped Information on the Experience of Parents of Children with Acute Lymphoblastic Leukemia. 61
30739269 2020
9
Acrophyseal growth arrest in a long-term survivor of acute lymphoblastic leukemia. 61
32564105 2020
10
Incidence trends of childhood acute lymphoblastic leukemia in Saudi Arabia: Increasing incidence or competing risks? 61
32559676 2020
11
Sex and Gender Considerations After Surviving Acute Lymphoblastic Leukemia: An Exercise Oncology Context. 61
31971841 2020
12
Maximal cardiopulmonary exercise testing in childhood acute lymphoblastic leukemia survivors exposed to chemotherapy. 61
32556714 2020
13
Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. 61
32519032 2020
14
Association of TLX1 gene polymorphisms with the risk of acute lymphoblastic leukemia and B lineage acute lymphoblastic leukemia in Han Chinese children. 61
32488880 2020
15
Metabolic reprogramming in childhood acute lymphoblastic leukemia. 61
32293782 2020
16
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. 61
32275469 2020
17
Prevalence and Risk Factors for Metabolic Syndrome Among Childhood Acute Lymphoblastic Leukemia Survivors: Experience From South India. 61
32516199 2020
18
The effect of cardiorespiratory fitness and physical activity levels on cognitive functions in survivors of childhood acute lymphoblastic leukemia. 61
32510265 2020
19
Simultaneous changes in expression levels of BAALC and miR-326: a novel prognostic biomarker for childhood ALL. 61
32129446 2020
20
Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity. 61
32176452 2020
21
Prenatal pesticide exposure and childhood leukemia - A California statewide case-control study. 61
32087503 2020
22
Inconsistencies between measures of cognitive dysfunction in childhood acute lymphoblastic leukemia survivors: Description and understanding. 61
32391960 2020
23
GPAA1 promotes progression of childhood acute lymphoblastic leukemia through regulating c-myc. 61
32432756 2020
24
Reciprocal Regulation of HSD11B1 and HSD11B2 Predicts Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. 61
31987650 2020
25
Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04-16. 61
32368831 2020
26
Early Recovery of Height Velocity in Prepubertal Children With Acute Lymphoblastic Leukemia Treated by a Short Intensive Phase Without Cranial Radiation Therapy. 61
31842181 2020
27
Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis. 61
32358392 2020
28
Single-cell analysis of childhood leukemia reveals a link between developmental states and ribosomal protein expression as a source of intra-individual heterogeneity. 61
32415257 2020
29
E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia. 61
32276273 2020
30
A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. 61
32315382 2020
31
[Epidemidogical Analysis of 982 Hospitalized Cases of Childhood Acute Lymphoblastic Leukemia]. 61
32319365 2020
32
Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL). 61
31870219 2020
33
Hand Mirror Cells and Hypercalcemia: A Rare Presentation of Pediatric Acute Lymphoblastic Leukemia. 61
30475304 2020
34
Concurrent Pituicytoma, Meningioma, and Cavernomas After Cranial Irradiation for Childhood Acute Lymphoblastic Leukemia. 61
31904435 2020
35
Seizures during treatment of childhood acute lymphoblastic leukemia: A population-based cohort study. 61
32340855 2020
36
History of Early Childhood Infections and Acute Lymphoblastic Leukemia Risk Among Children in a U.S. Integrated Health Care System. 61
32322901 2020
37
Frequency distribution of five SNPs in human GGH gene and their effects on clinical outcomes of Chinese pediatric patients with acute lymphoblastic leukemia. 61
32295690 2020
38
In vitro knock-out of miR-155 suppresses leukemic and HCV virus loads in pediatric HCV-4-associated acute lymphoid leukemia: A promising target therapy. 61
31696995 2020
39
Prednisolone Prophase for a Week Versus Upfront Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia: An Analysis With Reference to Induction Mortality in a Developing Country. 61
31688627 2020
40
Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. 61
32269320 2020
41
Spatial-Temporal Cluster Analysis of Childhood Cancer in California. 61
31596791 2020
42
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia. 61
31922920 2020
43
Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report. 61
31944498 2020
44
Insights into the prenatal origin of childhood acute lymphoblastic leukemia. 61
31902036 2020
45
Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants. 61
32221476 2020
46
Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan. 61
32108040 2020
47
Transcriptome Analysis Identifies LINC00152 as a Biomarker of Early Relapse and Mortality in Acute Lymphoblastic Leukemia. 61
32183133 2020
48
Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015. 61
31994344 2020
49
Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. 61
32320280 2020
50
Dexamethasone and neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. 61
31876055 2020

Variations for Childhood Acute Lymphocytic Leukemia

Copy number variations for Childhood Acute Lymphocytic Leukemia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 250737 9 21967751 21994490 Deletion CDKN2A pediatric acute lymphoblastic leukemia

Expression for Childhood Acute Lymphocytic Leukemia

Search GEO for disease gene expression data for Childhood Acute Lymphocytic Leukemia.

Pathways for Childhood Acute Lymphocytic Leukemia

GO Terms for Childhood Acute Lymphocytic Leukemia

Biological processes related to Childhood Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tetrahydrofolate interconversion GO:0035999 9.26 TYMS MTHFR
2 response to folic acid GO:0051593 9.16 TYMS MTHFR
3 folic acid metabolic process GO:0046655 9.13 SLC19A1 MTHFR DHFR
4 tetrahydrofolate metabolic process GO:0046653 8.8 TYMS MTHFR DHFR

Molecular functions related to Childhood Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 translation repressor activity, mRNA regulatory element binding GO:0000900 9.16 TYMS DHFR
2 sequence-specific mRNA binding GO:1990825 8.96 TYMS DHFR
3 folic acid binding GO:0005542 8.8 TYMS SLC19A1 DHFR

Sources for Childhood Acute Lymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....